<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liontos, M.</style></author><author><style face="normal" font="default" size="100%">Trigka, E.-A.</style></author><author><style face="normal" font="default" size="100%">P Korkolopoulou</style></author><author><style face="normal" font="default" size="100%">Tzannis, K.</style></author><author><style face="normal" font="default" size="100%">Lainakis, G.</style></author><author><style face="normal" font="default" size="100%">Koutsoukos, K.</style></author><author><style face="normal" font="default" size="100%">Kostouros, E.</style></author><author><style face="normal" font="default" size="100%">Lykka, M.</style></author><author><style face="normal" font="default" size="100%">Papandreou, C.N.</style></author><author><style face="normal" font="default" size="100%">Karavasilis, V.</style></author><author><style face="normal" font="default" size="100%">Christodoulou, C.</style></author><author><style face="normal" font="default" size="100%">Papatsoris, A.</style></author><author><style face="normal" font="default" size="100%">Skolarikos, A.</style></author><author><style face="normal" font="default" size="100%">Varkarakis, I.</style></author><author><style face="normal" font="default" size="100%">Adamakis, I.</style></author><author><style face="normal" font="default" size="100%">Alamanis, C.</style></author><author><style face="normal" font="default" size="100%">Stravodimos, K.</style></author><author><style face="normal" font="default" size="100%">Mitropoulos, D.</style></author><author><style face="normal" font="default" size="100%">Deliveliotis, C.</style></author><author><style face="normal" font="default" size="100%">Constantinidis, C.A.</style></author><author><style face="normal" font="default" size="100%">Saetta, A.</style></author><author><style face="normal" font="default" size="100%">Patsouris, E.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.Α.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients</style></title><secondary-title><style face="normal" font="default" size="100%">World Journal of Urology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">mRCC</style></keyword><keyword><style  face="normal" font="default" size="100%">mTOR</style></keyword><keyword><style  face="normal" font="default" size="100%">Sunitinib</style></keyword><keyword><style  face="normal" font="default" size="100%">VEGF</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978107446&amp;doi=10.1007%2fs00345-016-1890-7&amp;partnerID=40&amp;md5=68e45db77c26827cf8d30fd2ffea240a</style></url></web-urls></urls><pages><style face="normal" font="default" size="100%">1 - 9</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Purpose: To identify prognostic molecular profiles in patients with mRCC treated with sunitinib, we performed immunohistochemical analysis for VEGF and PI3K/Akt/mTOR pathway components. Methods: The immunohistochemical expression of VEGF, p85α, p110γ, PTEN, p-Akt, p-mTOR, p-4E-BP1 and p-p70S6K was studied in 79 patients with mRCC who received first-line treatment with sunitinib. Expression was correlated with clinicopathological features and survival. Results: VEGF was highly expressed (median H-Score 150), while positivity for the markers of the PI3K/Akt/mTOR pathway was: p85α 43/66 (65 %), p110γ41/60 (68 %), PTEN 32/64 (50 %), p-Akt57/63 (90 %), p-mTOR48/64 (75 %), p-4E-BP1 58/64 (90 %) and p-p70S6K 60/65 (92 %). No single immunohistochemical marker was found to have prognostic significance. Instead, the combination of increased p-mTOR and low VEGF expression was adversely correlated with overall survival (OS) (3.2 vs. 16.9 months, P = 0.001). Conclusion: Immunohistochemistry for VEGF and p-mTOR proteins may discriminate patients refractory to first-line sunitinib with poor prognosis. Prospective validation of our findings is needed. © 2016 Springer-Verlag Berlin Heidelberg</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 21 February 2017Article in Press</style></notes></record></records></xml>